Similarly, the OPTIMIST trial from Korea has been launched, which is a prospective, multicentre, non-inferiority trial of 5-year DFS in patients with TN and HER2-positive breast cancer who have no residual tumour confirmed by image-guided biopsy following NST when breast surgery has been foregone [29]. The gene discussed is ERBB2; the disease is breast carcinoma.